Patents by Inventor David J. Perkowski

David J. Perkowski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF RIBOSE IN FIRST RESPONSE TO ACUTE MYOCARDIAL INFARCTION
    Publication number: 20200206252
    Abstract: D-ribose is administered to patients suffering an acute myocardial infarction during first response care, in order to prevent cardiac compromise. In those patients able to ingest fluids, two to five grams of D-ribose is administered orally. In a patients unable to ingest fluids, or in a patient with and intravenous line, pyrogen-free D-ribose is administered intravenously at a rate of 50-300 mg/kg/hour.
    Type: Application
    Filed: March 8, 2019
    Publication date: July 2, 2020
    Inventors: John A. St. Cyr, David J. Perkowski
  • USE OF RIBOSE IN FIRST RESPONSE TO ACUTE MYOCARDIAL INFARCTION
    Publication number: 20170326165
    Abstract: D-ribose is administered to patients suffering an acute myocardial infarction during first response care, in order to prevent cardiac compromise. In those patients able to ingest fluids, two to five grams of D-ribose is administered orally. In a patients unable to ingest fluids, or in a patient with and intravenous line, pyrogen-free D-ribose is administered intravenously at a rate of 50-300 mg/kg/hour.
    Type: Application
    Filed: April 26, 2017
    Publication date: November 16, 2017
    Inventors: John A. St. Cyr, David J. Perkowski
  • Use of ribose in first response to acute myocardial infarction
    Publication number: 20100055206
    Abstract: D-ribose is administered to patients suffering an acute myocardial infarction during first response care, in order to prevent cardiac compromise. In those patients able to ingest fluids, two to five grams of D-ribose is administered orally. In a patients unable to ingest fluids, or in a patient with and intravenous line, pyrogen-free D-ribose is administered intravenously at a rate of 50-300 mg/kg/hour.
    Type: Application
    Filed: April 2, 2009
    Publication date: March 4, 2010
    Inventors: John A. St. Cyr, David J. Perkowski
  • Use Of Ribose for Recovery From Anaesthesia
    Publication number: 20090197818
    Abstract: D-Ribose is administered before and after general anaesthesia to reduce the time to recover from the effects of general anaesthesia. Preferably, pyrogen-free D-Ribose is administered intravenously during general anaesthesia and the interval post-anaesthesia before oral administration can be resumed. D-Glucose may be co-administered to reduce the effect of hypoglycemia that may be seen with D-Ribose administration.
    Type: Application
    Filed: January 14, 2005
    Publication date: August 6, 2009
    Inventors: John A. St. Cyr, David J. Perkowski